Sera from patients with toxic epidermal necrolysis contain autoantibodies to periplakin

British Journal of Dermatology

Volumn 155, Issue 2, 2006, Pages 337-343

  Park, G T ^a   Quan, G ^b   Lee, J B ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Autoantibodies; Periplakin; Toxic epidermal necrolysis

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G; PERIPLAKIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; BLADDER; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; EPIDERMIS; HUMAN; HUMAN TISSUE; IMMUNOADSORPTION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; TOXIC EPIDERMAL NECROLYSIS;

ANIMALS; AUTOANTIBODIES; EPIDERMAL NECROLYSIS, TOXIC; EPIDERMIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALE; MICE; PLAKINS; RATS; RECOMBINANT FUSION PROTEINS; TONGUE; URINARY BLADDER;

EID: 33745890648     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07323.x     Document Type: Article

References (26)

1. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-3.
2. Abe R, Shimizu T, Shibaki A et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003; 162:1515-20.
3. Amagai M, Klaus-Kovtun V, Stanley J. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67:869-77.
4. Labib RS, Anhalt GJ, Patel HP et al. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 1986; 136:1231-5.
5. Anhalt GJ. Paraneoplastic pemphigus. Adv Dermatol 1997; 12:77-96.
6. Borradori L, Trueb RM, Jaunin F et al. Autoantibodies from a patient with paraneoplastic pemphigus bind periplakin, a novel member of the plakin family. J Invest Dermatol 1998; 111:338-40.
7. Kim SC, Kwon YD, Lee IJ et al. cDNA cloning of the 210-kDa paraneoplastic pemphigus antigen reveals that envoplakin is s component of the antigen complex. J Invest Dermatol 1997; 109:365-9.
8. Mahoney MG, Aho S, Uitto J, Stanley JR. The members of the plakin family of proteins recognized by paraneoplastic pemphigus antibodies include periplakin. J Invest Dermatol 1998; 111:308-13.
9. Foedinger D, Anhalt GJ, Boecskoer B et al. Autoantibodies to desmoplakin I and II in patients with erythema multiforme. J Exp Med 1995; 181:169-79.
10. Foedinger D, Sterniczky B, Elbe A et al. Autoantibodies against desmoplakin I and II define a subset of patients with erythema multiforme major. J Invest Dermatol 1996; 106:1012-16.
11. Foedinger D, Elbe-Bürger A, Sterniczky B et al. Erythema multiforme associated human autoantibodies against desmoplakin I and II: biochemical characterization and passive transfer studies into newborn mice. J Invest Dermatol 1998; 111:503-10.
12. Ruhrberg C, Hajibagheri MN, Parry DA, Watt FM. Periplakin, a novel component of cornified envelopes and desmosomes that belongs to the plakin family and forms complexes with envoplakin. J Cell Biol 1997; 139:1835-49.
13. Ruhrberg C, Watt FM. The plakin family: versatile oraganizers of cytoskeletal architecture. Curr Opin Genet Dev 1997; 7:392-7.
14. Karashima T, Watt FM. Interaction of periplakin and envoplakin with intermediate filaments. J Cell Sci 2002; 115:5027-37.
15. Anhalt GJ, Kim S-C, Stanley JR et al. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323:1729-35.
16. Hashimoto T, Amagai M, Watanabe K et al. Charaterization of paraneoplastic pemphigus autoantibodies by immunoblot analysis. J Invest Dermatol 1995; 104:829-34.
17. Fritsch PO, Ruiz-Maldonado R. Erythema multiforme. In: Fitzpatrick's Dermatology in General Medicine (Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds), 6th edn. New York: McGraw-Hill, 2003; 543-57.
18. Hashimoto T, Ogawa MM, Konohana A, Nishikawa T. Detection of pemphigus vulgaris and pemphigus foliaceus antigens by immunoblot analysis using different antigen sources. J Invest Dermatol 1990; 94:327-31.
19. 2+-dependent vesicle binding. J Biol Chem 2004; 279:22773-80.
20. Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129:92-6.
21. Helou J, Allritton J, Anhalt GJ. Accuracy of indirect immunofluorescence testing in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 1995; 32:441-7.
22. Stanley JR. Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol 1993; 53:291-325.
23. Domloge-Hultsch N, Gammon WR, Briggaman RA et al. Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J Clin Invest 1992; 90:1628-33.
24. Garrod DR. Desmosomes and hemidesmosomes. Curr Opin Cell Biol 1993; 5:30-40.
25. Nagata Y, Karashima T, Watt FM et al. Paraneoplastic pemphigus sera react strongly with multiple epitopes on the various regions of envoplakin and periplakin, except for the C-terminal homologous domain of periplakin. J Invest Dermatol 2001; 116:556-63.
26. Bachot N, Revuz J, Roujeau J-C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139:33-6.